Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

18.2%

2 terminated/withdrawn out of 11 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

200%

4 of 2 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

N/A

2(28.6%)

Phase 1

1(14.3%)

7Total

Phase 2(4)

N/A(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT07499882Not Yet Recruiting

Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy

Role: collaborator

NCT05656794Phase 2Recruiting

Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer

Role: collaborator

NCT07483658Not ApplicableNot Yet Recruiting

Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.

Role: collaborator

NCT07310420Phase 1Not Yet Recruiting

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

Role: lead

NCT07460726Not Yet Recruiting

PRIAPUS-PCa Study: Stereotactic Body Radiation Therapy (SBRT) and Androgen Deprivation Therapy (ADT) Impact on Sexual Function on Men With Unfavorable Intermediate Risk Prostate Cancer

Role: collaborator

NCT05820633Not ApplicableSuspended

Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate Cancer.

Role: collaborator

NCT03133988Unknown

Margetuximab Expanded Access Program

Role: lead

NCT03223428Completed

Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO

Role: lead

NCT04189588Phase 2Completed

Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine